West Pharma Q3 EPS $1.85 (down from $2.14); raises FY2024 guidance, boosts dividend 5%

WEST PHARMACEUTICAL SERVICES INC

2024-Q3 EPS reported $4.91 revenue$2,144,400,000

Q3 net sales $746.9M flat YoY; reported EPS $1.85 vs $2.14; adjusted EPS $1.85 vs $2.16.
FY2024 guidance raised: net sales $2.875B-$2.905B, adjusted EPS $6.55-$6.75 (prior $6.35-$6.65).
Dividend increased 5% to $0.21/share, payable Nov 20, 2024, record Nov 13, 2024.
Proprietary Products net sales $601.4M (-0.2%); Contract-Manufactured $145.5M (+0.4%).
Nine-month free cash flow $191.2M (-32.7%); share repurchases $506.5M in 9M 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.